Diroximel fumarate
Diroximel fumarate (ALKS 8700) is an orally-active and well-tolerated monomethyl fumarate (MMF) proagent in a controlled-release formulation. Diroximel fumarate is considered as active equivalent to its active metabolite dimethyl fumarate (DMF) . Diroximel fumarate has a favorable safety and efficacy profile, has the potential for the study of multiple sclerosis (MS) . Diroximel fumarate is a Nrf2 activator that alleviate MGO-induced pain hypersensitivity[1][2].
Product Specifications
CAS Number
1577222-14-0
Product Name Alternative
ALKS 8700; BIIB098
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Keap1-Nrf2
Type
Reference compound
Related Pathways
NF-κB
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/diroximel-fumarate.html
Purity
99.60
Solubility
DMSO : 125 mg/mL (ultrasonic) |H2O : ≥ 10 mg/mL
Smiles
O=C(OCCN1C(CCC1=O)=O)/C=C/C(OC)=O
Molecular Formula
C11H13NO6
Molecular Weight
255.22
Precautions
H302, H315, H319, H335
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Ep-CAM / CD326 (VU-1D9), CF555 conjugate, 0.1mg/mL
CD35 / CR1 (E11), CF488A conjugate, 0.1mg/mL
Tyrosinase (T311 + OCA1/812), CF740 conjugate, 0.1mg/mL
